BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ravera M, Bussalino E, Paoletti E, Bellasi A, Di Lullo L, Fusaro M. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator? International Journal of Cardiology 2019;274:179-85. [DOI: 10.1016/j.ijcard.2018.07.066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Nabiee M, Dashti-khavidaki S, Khajeh B. Dose discordance of direct acting oral anticoagulants using different equations for estimating GFR: a literature review. Expert Review of Clinical Pharmacology 2020;13:857-63. [DOI: 10.1080/17512433.2020.1798759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ravera M, Bussalino E, Fusaro M, Di Lullo L, Aucella F, Paoletti E. Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist's perspective. J Nephrol 2020;33:483-95. [PMID: 32200488 DOI: 10.1007/s40620-020-00720-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Bobot M, Thomas L, Moyon A, Fernandez S, McKay N, Balasse L, Garrigue P, Brige P, Chopinet S, Poitevin S, Cérini C, Brunet P, Dignat-George F, Burtey S, Guillet B, Hache G. Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction. J Am Soc Nephrol 2020;31:1509-21. [PMID: 32527975 DOI: 10.1681/ASN.2019070728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
4 Leung KC, Macrae JM. Anticoagulation in CKD and ESRD. J Nephrol 2019;32:719-31. [DOI: 10.1007/s40620-019-00592-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Limdi NA, Beasley TM, Sun J, Stockbridge N, Pacanowski M, Florian J. Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function. Clin Pharmacol Ther 2021;109:1593-605. [PMID: 33278832 DOI: 10.1002/cpt.2131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tapoi L, Ureche C, Sascau R, Badarau S, Covic A. Atrial fibrillation and chronic kidney disease conundrum: an update. J Nephrol 2019;32:909-17. [DOI: 10.1007/s40620-019-00630-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shen Y, Wang J, Chen H, Li M, Chen M. Factors associated with renal impairment in Chinese patients with non-valvular AF and without an established renal disease: a cross-sectional study. Postgrad Med 2020;132:452-7. [PMID: 32174239 DOI: 10.1080/00325481.2020.1739914] [Reference Citation Analysis]
8 Magnocavallo M, Bellasi A, Mariani MV, Fusaro M, Ravera M, Paoletti E, Di Iorio B, Barbera V, Della Rocca DG, Palumbo R, Severino P, Lavalle C, Di Lullo L. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. J Clin Med 2020;10:E83. [PMID: 33379379 DOI: 10.3390/jcm10010083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, Goldsmith D. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol 2019;74:2204-15. [PMID: 31648714 DOI: 10.1016/j.jacc.2019.08.1031] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]